In Massachusetts, Audax Medical, Inc. has a worldwide license from Northeastern University for new nanotechnology of a self-assembling arginine-rich peptide to add to its current tissue regeneration platform. They plan to use this new nanotech for their medical applications and tissue regeneration. The newly developed nanostructures have antimicrobial properties, but unlike antibiotics which go after specific cellular activity, the nanoparticles aim specifically for the microorganisms’ cytoplasmic membrane which limits the inflammation and infection in surrounding tissue. Mark Johanson, Audax’s CEO, told PR Newswire, “We are excited to be collaborating with Northeastern’s team of world-class researchers. This technology fits perfectly with our company’s core biologics platform, while expanding potential clinical opportunities in the growing Wound Care and Anti-Infection markets.”
Latest article
Dutch Queen promotes biobased building materials
In the Netherlands, Dutch Queen consort Máxima visited two Uden worksites promoting biobased building materials made from Netherlands fiber crops.
The March 26 visit...
ReefCircular launches crowdfunding campaign for shell bioconcrete
In Denmark, ReefCircular, a company developing a shell-based bioconcrete to help restore marine habitats, has launched a crowdfunding campaign on Kickstarter.
The company’s bioconcrete...
Aleph Farms raises $29 million for lab-grown steak
In Israel, cultivated meat producer Aleph Farms has raised $29 million to expand production at its Rehovot pilot plant and expand production into Europe...